GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » Net Change in Cash

Mirum Pharmaceuticals (FRA:08D) Net Change in Cash : €-59.1 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Mirum Pharmaceuticals's Net Change in Cash for the three months ended in Jun. 2024 was €-64.4 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was €-59.1 Mil.

Mirum Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Mirum Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Net Change in Cash Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial -35.99 106.96 -9.51 -3.15 145.18

Mirum Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.43 5.46 -15.34 15.20 -64.43

Mirum Pharmaceuticals Net Change in Cash Calculation

Mirum Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-65.056+-98.302+308.662+-0.122
=145.2

Mirum Pharmaceuticals's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.533+-67.554+6.773+-0.111
=-64.4

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-59.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » Net Change in Cash
Comparable Companies
XNCR BCRX DAWN IRON AUPH AMLX CLDX VIR GERN SLRN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MIRM:USA MIRM:Mexico
Address
950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404
Website
https://www.mirumpharma.com
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals Headlines

No Headlines